Cancer is one of the leading causes of death worldwide, making early and accurate diagnosis essential for improving survival and treatment outcomes. Next Generation Sequencing (NGS) has transformed cancer care, enabling rapid, precise detection of genetic mutations that drive disease. Today, NGS powers breakthroughs in diagnosis, prognosis, and therapy selection, paving the way for personalized medicine and more effective treatment strategies. Genes2Me CancerCheck 100 Assay is an advanced NGS-based solution featuring a curated 148 gene panel designed to detect all variant types, including germline and somatic mutations, from blood or tumor tissue. By focusing on clinically relevant cancer genes with exceptional sensitivity and specificity, this assay enables early detection, accurate diagnosis, and personalized treatment planning while optimizing cost and workflow efficiency. The panel provides comprehensive detail of the biomarkers such as MSIs & HRR genes in cancer and helps to decide the best course of treatment.
| Key features & highlights | |
|---|---|
| Extensive Gene Coverage: Screens 148 cancer associated genes, including ~99 gene families, for comprehensive mutation analysis. | |
| Whole Coding Region Sequencing: Covers the entire CDS region (~0.5 Mb target size) for high-resolution variant detection. | |
| Broad Mutation Detection: Identifies SNVs, InDels, CNVs, and key biomarkers such as MSI and HRR genes, critical for cancer risk assessment. | |
| Dual Sample Compatibility: Works with blood and FFPE tumor tissue, enabling flexibility for clinical and research applications. | |
| Precision Oncology Support: Facilitates early diagnosis, personalized treatment planning, and informed decisions for targeted therapies. | |
| Number of Genes: | 148 |
| Gene count/family: | ~99 |
| Target Size: | 0.5 Mb |
| Covered Regions: | Whole Coding Sequence |
| Mutation Types: | SNV / InDels / CNVs |
| Biomarkers: | MSI, HRR Genes |
| Sample Type: | Blood / FFPE |
| Platform Compatibility: | Illumina, MGI, Thermo Fisher, Element Biosciences |
| Features | Performance |
|---|---|
| Coverage uniformity (0.2X) | >99% |
| Reproducibility (%) | 97 |
| Sensitivity (%) | 98.9 |
| On Target Ratio (%) | 78-85 |
On-target ratio across cancer patient samples:
All patient samples achieved more than 75% on-target alignment, reflecting the panel’s exceptional design precision, optimized assay performance, and highly efficient target capture ensuring reliable, high-quality sequencing efficiency.
Coverage of Key Cancer Genes Across Sample Types:
Mean coverage profiles of pivotal cancer-associated genes (ALK, APC, BRAF, TP53, and RET) demonstrate uniform and consistent target representation. The plot showing consistent coverage across targets highlights the robustness and reliability of the workflow, ensuring high-quality performance and confidence in routine clinical testing across diverse FFPE samples.
| Commercial Name | Cat No. | Pack Size | Platform |
|---|---|---|---|
| CancerCheck-100 NGS Test Kit | G710005-1 | 24 T | Illumina |
| G710005-2 | 96 T | Illumina | |
| G710005-3 | 96 T – EZY | Illumina – EZY | |
| CancerCheck-100 NGS Test Kit | G710005-4 | 24 T | MGI |
| G710005-5 | 96 T | MGI | |
| G710005-6 | 96 T – EZY | MGI – EZY | |
| CancerCheck-100 NGS Test Kit | G710005-7 | 24 T | Aviti |
| G710005-8 | 96 T | Aviti | |
| G710005-9 | 96 T – EZY | Aviti – EZY | |
| CancerCheck-100 NGS Test Kit | G710005-10 | 24 T | Thermo |
| G710004-11 | 96 T | Thermo | |
| G710005-12 | 96 T – EZY | Thermo – EZY |
Download useful documents and technical information for the CancerCheck 100 Assay
Since its inception in 2016, Genes2me has been constantly striving towards setting a benchmark in the diagnostics space by introducing premium quality (Made in India) diagnostic kits which are CE-IVD, ISO-13485:2016, and ISO 9001:2015 certified, assuring our clients of unparalleled quality and compliance with international standards.
All products listed in the catalogue are the products of Genes2Me Private Limited. Apart from that, all other product names, trademarks and logos wherever used in the catalogue are the property of their respective owners.
© 2025 Genes2me. All rights reserved.
